Historical perspective and advances in the treatment of multiple myeloma

  • Amir Harandi | a0hara01@gwise.louisville.edu Brown Cancer Center, University of Louisville Louisville, United States.
  • Damian A. Laber Brown Cancer Center, University of Louisville Louisville, United States.

Abstract

Corticosteroids and melphalan were used for decades to treat multiple myeloma. Combination chemotherapy has been extensively studied with similar overall survival rates to melphalan and prednisone. In the last decade, the development of new agents has progressed significantly. Thalidomide and its newer derivatives lenalidomide, bortezomib, and pegylated liposomal doxorubicin have drastically revolutionized treatment approaches. As a result, numerous clinical trials have yielded exciting treatment strategies resulting in therapeutic advances, and improved responses and overall survival of patients. This review summarizes the international uniform response criteria for multiple myeloma and gives a historical perspective on previous therapies with updates on the newest available treatments.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-12-18
Info
Issue
Section
Reviews
Keywords:
Multiple myeloma - Chemotherapy - Advances in treatment
Statistics
  • Abstract views: 1198

  • FULL TEXT: 282
How to Cite
Harandi, A., & Laber, D. A. (2011). Historical perspective and advances in the treatment of multiple myeloma. Oncology Reviews, 2(4), 250-258. https://doi.org/10.4081/oncol.2008.133